Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Short-term Investments (2017 - 2025)

Cue Biopharma (CUE) has disclosed Short-term Investments for 8 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 17.65% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 17.65% year-over-year, with the annual reading at $1.1 million for FY2025, 17.65% up from the prior year.
  • Short-term Investments hit $1.1 million in Q4 2025 for Cue Biopharma, down from $7.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $29.5 million in Q3 2022 to a low of $287000.0 in Q4 2023.
  • Historically, Short-term Investments has averaged $8.0 million across 4 years, with a median of $3.0 million in 2023.
  • Biggest five-year swings in Short-term Investments: tumbled 98.84% in 2023 and later skyrocketed 223.69% in 2024.
  • Year by year, Short-term Investments stood at $24.7 million in 2022, then crashed by 98.84% to $287000.0 in 2023, then surged by 223.69% to $929000.0 in 2024, then increased by 17.65% to $1.1 million in 2025.
  • Business Quant data shows Short-term Investments for CUE at $1.1 million in Q4 2025, $7.0 million in Q3 2025, and $470000.0 in Q2 2025.